Actiste® Mini receives market approval in the United Arab Emirates
Brighter AB (publ) is proud to announce that the diabetes management device Actiste® Mini today received market approval from the Ministry of Health & Prevention in the UAE.
Actiste® Mini is a smart and user-friendly blood glucose meter with global out-of-the-box internet connectivity through eSIM, aiming to support successful diabetes management and monitoring.
"We still need to get some internal and external go-to-market processes and preparations in place but we are very pleased to have reached this significant milestone in the commercialization of the Actiste portfolio. With all relevant medical device approvals for both Actiste® Mini and the original Actiste® service designed for insulin treated diabetes, Brighter can now address the whole diabetes community in the UAE,” says Christer Trägårdh, acting CEO of Brighter.
For further information, please contact:
Investor Relations
IR@brighter.se
Christer Trägårdh, Acting CEO
christer.tragardh@brighter.se
Certified Adviser
Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10, adviser@eminova.se, www.eminova.se.
About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.
This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 18:15 CET on March 21, 2021.